Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 1.75
ALKS's Cash-to-Debt is ranked lower than
73% of the 864 Companies
in the Global Biotechnology industry.

( Industry Median: 53.59 vs. ALKS: 1.75 )
Ranked among companies with meaningful Cash-to-Debt only.
ALKS' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.43  Med: 1.64 Max: No Debt
Current: 1.75
Equity-to-Asset 0.70
ALKS's Equity-to-Asset is ranked higher than
57% of the 635 Companies
in the Global Biotechnology industry.

( Industry Median: 0.65 vs. ALKS: 0.70 )
Ranked among companies with meaningful Equity-to-Asset only.
ALKS' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.02  Med: 0.62 Max: 0.87
Current: 0.7
-0.02
0.87
Piotroski F-Score: 5
Altman Z-Score: 10.11
Beneish M-Score: -2.79
WACC vs ROIC
17.87%
-20.32%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % -27.98
ALKS's Operating Margin % is ranked higher than
61% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: -97.80 vs. ALKS: -27.98 )
Ranked among companies with meaningful Operating Margin % only.
ALKS' s Operating Margin % Range Over the Past 10 Years
Min: -35.7  Med: -18.36 Max: 41.29
Current: -27.98
-35.7
41.29
Net Margin % -27.95
ALKS's Net Margin % is ranked higher than
60% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: -83.37 vs. ALKS: -27.95 )
Ranked among companies with meaningful Net Margin % only.
ALKS' s Net Margin % Range Over the Past 10 Years
Min: -36.15  Med: -13.55 Max: 69.37
Current: -27.95
-36.15
69.37
ROE % -16.70
ALKS's ROE % is ranked higher than
65% of the 773 Companies
in the Global Biotechnology industry.

( Industry Median: -39.29 vs. ALKS: -16.70 )
Ranked among companies with meaningful ROE % only.
ALKS' s ROE % Range Over the Past 10 Years
Min: -18.25  Med: -5.96 Max: 65.64
Current: -16.7
-18.25
65.64
ROA % -11.75
ALKS's ROA % is ranked higher than
68% of the 870 Companies
in the Global Biotechnology industry.

( Industry Median: -33.51 vs. ALKS: -11.75 )
Ranked among companies with meaningful ROA % only.
ALKS' s ROA % Range Over the Past 10 Years
Min: -12.04  Med: -4.55 Max: 27.26
Current: -11.75
-12.04
27.26
ROC (Joel Greenblatt) % -60.24
ALKS's ROC (Joel Greenblatt) % is ranked higher than
68% of the 827 Companies
in the Global Biotechnology industry.

( Industry Median: -476.30 vs. ALKS: -60.24 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ALKS' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -61.03  Med: -16.97 Max: 131.93
Current: -60.24
-61.03
131.93
3-Year Revenue Growth Rate 5.50
ALKS's 3-Year Revenue Growth Rate is ranked higher than
51% of the 485 Companies
in the Global Biotechnology industry.

( Industry Median: 4.80 vs. ALKS: 5.50 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
ALKS' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -20.2  Med: 7.4 Max: 69.6
Current: 5.5
-20.2
69.6
GuruFocus has detected 3 Warning Signs with Alkermes PLC $ALKS.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ALKS's 10-Y Financials

Financials (Next Earnings Date: 2017-05-15 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

ALKS Guru Trades in Q1 2016

Paul Tudor Jones 21,964 sh (+223.86%)
Pioneer Investments 345,537 sh (+65.55%)
Vanguard Health Care Fund 8,603,676 sh (+25.56%)
Murray Stahl 25,000 sh (unchged)
Jim Simons Sold Out
George Soros Sold Out
Ken Fisher 120,297 sh (-0.02%)
Jeff Auxier 26,751 sh (-0.37%)
» More
Q2 2016

ALKS Guru Trades in Q2 2016

PRIMECAP Management 2,505,450 sh (New)
Ken Fisher 123,094 sh (+2.33%)
Murray Stahl 25,000 sh (unchged)
Jeff Auxier 26,751 sh (unchged)
Vanguard Health Care Fund 8,603,676 sh (unchged)
Paul Tudor Jones Sold Out
Pioneer Investments 249,164 sh (-27.89%)
» More
Q3 2016

ALKS Guru Trades in Q3 2016

George Soros 4,600 sh (New)
PRIMECAP Management 3,153,560 sh (+25.87%)
Ken Fisher 129,607 sh (+5.29%)
Murray Stahl 25,000 sh (unchged)
Jeff Auxier 26,751 sh (unchged)
Vanguard Health Care Fund 8,603,676 sh (unchged)
Pioneer Investments 155,087 sh (-37.76%)
» More
Q4 2016

ALKS Guru Trades in Q4 2016

Steven Cohen 84,400 sh (New)
PRIMECAP Management 6,376,270 sh (+102.19%)
George Soros 7,200 sh (+56.52%)
Vanguard Health Care Fund 8,660,076 sh (+0.66%)
Murray Stahl 25,000 sh (unchged)
Jeff Auxier 26,751 sh (unchged)
Ken Fisher 118,407 sh (-8.64%)
Pioneer Investments 103,137 sh (-33.50%)
» More
» Details

Insider Trades

Latest Guru Trades with ALKS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:SGEN, NAS:TSRO, NAS:JAZZ, OTCPK:NVZMY, NAS:UTHR, NAS:EXEL, OTCPK:GMXAY, NAS:GRFS, NAS:BIVV, NAS:IONS, NAS:ARIA, NAS:ALNY, NAS:MDVN, NAS:KITE, NAS:ACAD, NAS:TECH, NAS:GLPG, NAS:BLUE, OTCPK:UCBJF, NAS:NKTR » details
Traded in other countries:8AK.Germany,
Alkermes PLC is a biotechnology company engaged in developing, manufacturing & commercializing medicines. The Company has a portfolio of commercial drug products & a clinical pipeline of product candidates that address central nervous system disorders.

Alkermes is a fully integrated global biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in major therapeutic areas. The company utilizes several collaborative arrangements to develop and commercialize products and, in so doing, to access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies.

Ratios

vs
industry
vs
history
Forward PE Ratio 1111.11
ALKS's Forward PE Ratio is ranked lower than
100% of the 84 Companies
in the Global Biotechnology industry.

( Industry Median: 20.12 vs. ALKS: 1111.11 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PB Ratio 7.51
ALKS's PB Ratio is ranked lower than
76% of the 1091 Companies
in the Global Biotechnology industry.

( Industry Median: 3.76 vs. ALKS: 7.51 )
Ranked among companies with meaningful PB Ratio only.
ALKS' s PB Ratio Range Over the Past 10 Years
Min: 1.66  Med: 4.26 Max: 61.08
Current: 7.51
1.66
61.08
PS Ratio 12.13
ALKS's PS Ratio is ranked higher than
52% of the 854 Companies
in the Global Biotechnology industry.

( Industry Median: 12.99 vs. ALKS: 12.13 )
Ranked among companies with meaningful PS Ratio only.
ALKS' s PS Ratio Range Over the Past 10 Years
Min: 2.21  Med: 7.1 Max: 18.81
Current: 12.13
2.21
18.81
Current Ratio 3.73
ALKS's Current Ratio is ranked lower than
53% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: 4.03 vs. ALKS: 3.73 )
Ranked among companies with meaningful Current Ratio only.
ALKS' s Current Ratio Range Over the Past 10 Years
Min: 2.74  Med: 5.36 Max: 15.38
Current: 3.73
2.74
15.38
Quick Ratio 3.43
ALKS's Quick Ratio is ranked lower than
53% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: 3.74 vs. ALKS: 3.43 )
Ranked among companies with meaningful Quick Ratio only.
ALKS' s Quick Ratio Range Over the Past 10 Years
Min: 2.69  Med: 5 Max: 15.38
Current: 3.43
2.69
15.38
Days Inventory 138.28
ALKS's Days Inventory is ranked lower than
52% of the 384 Companies
in the Global Biotechnology industry.

( Industry Median: 132.21 vs. ALKS: 138.28 )
Ranked among companies with meaningful Days Inventory only.
ALKS' s Days Inventory Range Over the Past 10 Years
Min: 86.09  Med: 128.98 Max: 166.33
Current: 138.28
86.09
166.33
Days Sales Outstanding 93.54
ALKS's Days Sales Outstanding is ranked lower than
70% of the 535 Companies
in the Global Biotechnology industry.

( Industry Median: 59.11 vs. ALKS: 93.54 )
Ranked among companies with meaningful Days Sales Outstanding only.
ALKS' s Days Sales Outstanding Range Over the Past 10 Years
Min: 27.46  Med: 82.14 Max: 93.54
Current: 93.54
27.46
93.54
Days Payable 127.84
ALKS's Days Payable is ranked higher than
72% of the 353 Companies
in the Global Biotechnology industry.

( Industry Median: 58.37 vs. ALKS: 127.84 )
Ranked among companies with meaningful Days Payable only.
ALKS' s Days Payable Range Over the Past 10 Years
Min: 39.15  Med: 65.98 Max: 127.84
Current: 127.84
39.15
127.84

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -4.50
ALKS's 3-Year Average Share Buyback Ratio is ranked higher than
74% of the 563 Companies
in the Global Biotechnology industry.

( Industry Median: -10.90 vs. ALKS: -4.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ALKS' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -15.4  Med: -8.5 Max: 2.1
Current: -4.5
-15.4
2.1

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 33.19
ALKS's Price-to-Net-Current-Asset-Value is ranked lower than
91% of the 870 Companies
in the Global Biotechnology industry.

( Industry Median: 5.79 vs. ALKS: 33.19 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
ALKS' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 3.21  Med: 18.28 Max: 55.9
Current: 33.19
3.21
55.9
Price-to-Tangible-Book 11.40
ALKS's Price-to-Tangible-Book is ranked lower than
82% of the 1017 Companies
in the Global Biotechnology industry.

( Industry Median: 4.44 vs. ALKS: 11.40 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
ALKS' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.65  Med: 10.49 Max: 230.67
Current: 11.4
2.65
230.67
Price-to-Intrinsic-Value-Projected-FCF 10.50
ALKS's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
75% of the 204 Companies
in the Global Biotechnology industry.

( Industry Median: 3.58 vs. ALKS: 10.50 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
ALKS' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 2.3  Med: 3.71 Max: 10.77
Current: 10.5
2.3
10.77
Price-to-Median-PS-Value 1.71
ALKS's Price-to-Median-PS-Value is ranked lower than
76% of the 750 Companies
in the Global Biotechnology industry.

( Industry Median: 1.02 vs. ALKS: 1.71 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ALKS' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.5  Med: 1.78 Max: 14.41
Current: 1.71
0.5
14.41
Earnings Yield (Greenblatt) % -2.19
ALKS's Earnings Yield (Greenblatt) % is ranked higher than
67% of the 1273 Companies
in the Global Biotechnology industry.

( Industry Median: -8.24 vs. ALKS: -2.19 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ALKS' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -2.31  Med: 2.6 Max: 53.4
Current: -2.19
-2.31
53.4

More Statistics

Revenue (TTM) (Mil) $745.7
EPS (TTM) $ -1.37
Beta2.33
Short Percentage of Float7.83%
52-Week Range $30.03 - 62.50
Shares Outstanding (Mil)152.55

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 903 1,098 1,384
EPS ($) 0.05 0.66 1.70
EPS without NRI ($) 0.05 0.66 1.70
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for ALKS

Headlines

Articles On GuruFocus.com
Who Is Winning the Fight Against Opioid Abuse? Feb 27 2017 
Naltrexone Showing More Potential in Drug Addiction Treatment Market Feb 05 2017 
BioCorRx Receives New Funding for Opioid Drug Jan 22 2017 
US Prisons Experiment With Addiction Treatment for Inmates Nov 29 2016 
AvalonBay Communities, Equinix, Jarden, Alkermes Approach 52-Week Highs Jan 04 2016 
Best Health Care Investor Edward Owens Buys One New Health Care Stock in First Quarter Apr 30 2012 
Weekly CEO Sells Highlight: Herbalife, CNO Financial Group, Alkermes plc, and TransDigm Oct 08 2011 
Alkermes Inc. Reports Operating Results (10-Q) Feb 03 2011 
Weekly Guru Bargains Highlights: SKX, VRX, ALKS, DF, SVU Dec 05 2010 
Alkermes Inc. Reports Operating Results (10-Q) Nov 04 2010 

More From Other Websites
Alkermes to Present Preclinical Data on ALKS 4230 at the American Association for Cancer Research... Mar 27 2017
Alkermes to Present Preclinical Data on ALKS 4230 at the American Association for Cancer Research... Mar 27 2017
Alkermes to Present Data on Two-Month Dosing Option Of ARISTADA® at 16th International Congress on... Mar 20 2017
Alkermes to Present Data on Two-Month Dosing Option Of ARISTADA® at 16th International Congress on... Mar 20 2017
Companies Aiming for the Billion-Dollar Opioid Addiction Market Mar 18 2017
Alkermes Starts Phase III Study to Treat Multiple Sclerosis Mar 17 2017
Alkermes Initiates Phase 3 Gastrointestinal Tolerability Study of ALKS 8700 for Treatment of... Mar 16 2017
Alkermes Initiates Phase 3 Gastrointestinal Tolerability Study of ALKS 8700 for Treatment of... Mar 16 2017
Alkermes Plc breached its 50 day moving average in a Bearish Manner : ALKS-US : March 14, 2017 Mar 14 2017
ALKERMES PLC. Files SEC form 8-K, Other Events Mar 10 2017
[video]The 'Gnarly 9' Biotechs Will Test the FDA's Mettle Mar 08 2017
The 'Gnarly 9' Biotechs Will Test the FDA's Mettle Mar 08 2017
Alkermes’ Corporate Presentation to be Webcast at the Barclays Global Healthcare Conference Mar 07 2017
Here’s What Mott Capital Management Thinks About Netflix, Alkermes, Vodafone & More Mar 02 2017
Alkermes’ Corporate Presentation to be Webcast at the Cowen and Company 37th Annual Health Care... Feb 28 2017
Alkermes’ Corporate Presentation to be Webcast at the Cowen and Company 37th Annual Health Care... Feb 28 2017
Drug Addiction Treatment Stocks to Watch Feb 22 2017
ALKERMES PLC. Financials Feb 22 2017
Alkermes Plc :ALKS-US: Earnings Analysis: 2016 By the Numbers : February 17, 2017 Feb 17 2017
ALKERMES PLC. Files SEC form 10-K, Annual Report Feb 17 2017
Stress boom to boost drug sales? Feb 16 2017
Alkermes (ALKS) Q4 Loss Narrower than Expectations, Sales Beat Feb 16 2017
Alkermes Plc :ALKS-US: Earnings Analysis: Q4, 2016 By the Numbers : February 16, 2017 Feb 16 2017
Edited Transcript of ALKS earnings conference call or presentation 15-Feb-17 1:30pm GMT Feb 15 2017
Alkermes reports 4Q loss Feb 15 2017
Alkermes plc Reports Financial Results for the Year Ended Dec. 31, 2016 and Provides Financial... Feb 15 2017
Alkermes to Host Conference Call to Discuss Fourth Quarter and Year-End 2016 Financial Results Feb 08 2017
Alkermes’ Corporate Presentation to be Webcast at the 35th Annual J.P. Morgan Healthcare... Jan 03 2017
Alkermes’ Corporate Presentation to be Webcast at the 35th Annual J.P. Morgan Healthcare... Jan 03 2017
Alkermes’ Corporate Presentation to be Webcast at the Jefferies 2016 London Healthcare Conference Nov 09 2016
Alkermes’ Corporate Presentation to be Webcast at the Jefferies 2016 London Healthcare Conference Nov 09 2016
ALKERMES Inspiration Grants™ Awarded to Support People Affected by Mental Health and Substance Use... Nov 03 2016
ALKERMES Inspiration Grants™ Awarded to Support People Affected by Mental Health and Substance Use... Nov 03 2016
Alkermes plc Reports Third Quarter 2016 Financial Results Nov 02 2016
Alkermes plc Reports Third Quarter 2016 Financial Results Nov 02 2016
Alkermes’ Corporate Presentation to be Webcast at the Credit Suisse 25th Annual Healthcare... Nov 01 2016
Alkermes’ Corporate Presentation to be Webcast at the Credit Suisse 25th Annual Healthcare... Nov 01 2016
Alkermes to Host Conference Call to Discuss Third Quarter 2016 Financial Results Oct 26 2016
Alkermes to Host Conference Call to Discuss Third Quarter 2016 Financial Results Oct 26 2016
Alkermes Announces Positive Topline Results From FORWARD-5 Pivotal Phase 3 Study of ALKS 5461 for... Oct 20 2016
Alkermes Announces Positive Topline Results From FORWARD-5 Pivotal Phase 3 Study of ALKS 5461 for... Oct 20 2016
Alkermes Announces Initiation of Clinical Study Evaluating Metabolic Profile of ALKS 3831 for... Oct 03 2016
Alkermes Announces Initiation of Clinical Study Evaluating Metabolic Profile of ALKS 3831 for... Oct 03 2016
Alkermes Announces Webcast of Analyst and Investor Event on September 26, 2016 Sep 19 2016
Alkermes Announces Webcast of Analyst and Investor Event on September 26, 2016 Sep 19 2016
Alkermes Launches Competitive Grants Program to Support People Affected by Mental Health and... Sep 12 2016
Alkermes’ Corporate Presentation to be Webcast at the Morgan Stanley Global Healthcare Conference Sep 06 2016
Alkermes’ Corporate Presentation to be Webcast at the Morgan Stanley Global Healthcare Conference Sep 06 2016
Alkermes Submits Supplemental New Drug Application to FDA for Two-Month Dosing Option of ARISTADA®... Aug 08 2016
Alkermes Submits Supplemental New Drug Application to FDA for Two-Month Dosing Option of ARISTADA®... Aug 08 2016
Alkermes plc Reports Second Quarter 2016 Financial Results Jul 28 2016
Alkermes plc Reports Second Quarter 2016 Financial Results Jul 28 2016
Alkermes’ Corporate Presentation to Be Webcast at the Goldman Sachs 37th Annual Global Healthcare... Jun 01 2016
Alkermes’ Corporate Presentation to Be Webcast at the Goldman Sachs 37th Annual Global Healthcare... Jun 01 2016
Alkermes Appoints Nancy Snyderman, M.D., to Board of Directors May 26 2016
Alkermes Appoints Nancy Snyderman, M.D., to Board of Directors May 26 2016
Alkermes Announces Initiation of Phase 1 Clinical Study of Immuno-Oncology Drug Candidate ALKS 4230 May 25 2016
Alkermes to Present Data on ALKS 5461 at Upcoming American Society of Clinical Psychopharmacology... May 24 2016
Alkermes Announces Plan to Initiate Second Clinical Trial of ALKS 7119 Based on Preliminary Phase 1... Apr 28 2016
Alkermes plc Reports First Quarter 2016 Financial Results Apr 28 2016
Alkermes to Host Conference Call to Discuss First Quarter 2016 Financial Results Apr 21 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)